Diplomat Pharmacy on Wednesday shared the financial results for its third quarter ended Sept. 30, showing increases in revenue and dispensed prescriptions, but also a drop in profit per prescription dispensed and its gross margin.
Bloomberg BNA is reporting that the Food and Drug Administration’s director of the Center for Drug Evaluation and Research’s Office of New Drugs told an audience at the DIA Biosimilars Conference that manufacturers looking to submit an application for biosimilar approval should know what the FDA is looking for when evaluating a biosmilar for approval. Jenkins said that rather than the focus on safety and efficacy it places on standalone biologics, with biosimilars, it focvuses on how closely it resembles the reference product, something he called “a work in progress” for some drug makers. (Bloomberg BNA)
Crain’s Detroit Business is reporting that Flint, Mich.-based Diplomat Pharmacy’s stock is feeling the effect of Tuesday announcement that president Gary Kadlec and the company’s CFO Sean Whelan would be departing the company by year’s end. After the announcement, the company’s shares fell 12.36% Wednesday, the report says, hitting a new 52-week low. The company is set to release its Q3 earnings report next week. (Crain’s Detroit Business)